Literature DB >> 12959321

Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity.

K A Bachmann1, T J Sullivan, L Jauregui, J H Reese, K Miller, L Levine.   

Abstract

The effects of omeprazole (40 mg orally per day) and nizatidine (300 mg orally per day) on the disposition of phenytoin (4.5 mg kg(-1) p.o. single dose) were studied in 18 healthy, young adult males. Total and unbound plasma concentrations of phenytoin were measured for 48 h after each dose of phenytoin. Neither treatment altered the disposition kinetics of phenytoin, the hydroxylation of which is mediated specifically by cytochromes P450 of the 2C subfamily.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 12959321      PMCID： PMC1364696          DOI： 10.1111/j.1365-2125.1993.tb00382.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

2.  Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients.

Authors:  K Bachmann; T J Sullivan; L S Mauro; M Martin; L Jauregui; L Levine
Journal:  J Clin Pharmacol       Date:  1992-05       Impact factor: 3.126

3.  A study of the interaction between omeprazole and phenytoin in epileptic patients.

Authors:  T Andersson; P O Lagerström; P Unge
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

4.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

Authors:  M E Veronese; P I Mackenzie; C J Doecke; M E McManus; J O Miners; D J Birkett
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

5.  Oral phenytoin pharmacokinetics during omeprazole therapy.

Authors:  P J Prichard; R P Walt; G K Kitchingman; K W Somerville; M J Langman; J Williams; A Richens
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

6.  Co-regulation of phenytoin and tolbutamide metabolism in humans.

Authors:  W Tassaneeyakul; M E Veronese; D J Birkett; C J Doecke; M E McManus; L N Sansom; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

7.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.

Authors:  M E Veronese; C J Doecke; P I Mackenzie; M E McManus; J O Miners; D L Rees; R Gasser; U A Meyer; D J Birkett
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

8.  Effect of five structurally diverse H2-receptor antagonists on drug metabolism.

Authors:  M Pasanen; P Arvela; O Pelkonen; E Sotaniemi; U Klotz
Journal:  Biochem Pharmacol       Date:  1986-12-15       Impact factor: 5.858

9.  Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

Authors:  R Gugler; J C Jensen
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682
  9 in total
  6 in total

Review 1.  Drug interactions with proton pump inhibitors.

Authors:  P Unge; T Andersson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 2.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

3.  Omeprazole induces gastric permeability to digoxin.

Authors:  M Gabello; M C Valenzano; M Barr; P Zurbach; J M Mullin
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

Review 4.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

5.  Lansoprazole does not affect the bioavailability of oral contraceptives.

Authors:  W Fuchs; R Sennewald; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 6.  Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole.

Authors:  T Andersson; M Hassan-Alin; G Hasselgren; K Röhss
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.